The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to ...
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...